Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo Control Phase 1b/II Study to Evaluate the Safety and Efficacy of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

NCT06535412 is registered in ClinicalTrials.gov with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06535412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06535412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo Control Phase 1b/II Study to Evaluate the Safety and Efficacy of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
Lead sponsor
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 10, 2024
Completion date
December 17, 2028
Enrollment
218 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus